

Stockholm

25 October 2024

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Wednesday 27 November 2024 at 11:00 a.m. CET at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 10:30 a.m. CET.

Right to participate in the extraordinary general meeting and notice of participation

A shareholder who wishes to participate in the general meeting must (i) be recorded as a shareholder in the share register maintained by Euroclear Sweden AB relating to the circumstances on 19 November 2024, and (ii) no later than 21 November 2024 give notice by post to Calliditas Therapeutics AB (publ), Extraordinary General Meeting 2024, c/o Euroclear Sweden, Box 191, SE-101 23 Stockholm, Sweden or via e-mail to GeneralMeetingService@euroclear.com. When providing such notice, the shareholder shall state name, personal or corporate registration number, address, telephone number and the number of any accompanying assistant(s) (maximum two assistants) as well as information about any proxy.

If a shareholder is represented by proxy, a written, dated proxy for the representative must be issued. If the proxy is issued by a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. To facilitate the registration at the general meeting, the proxy and the certificate of registration or equivalent certificate of authority should be sent to the company as set out above so that it is received no later than 26 November 2024.

Nominee-registered shares

To be entitled to participate in the general meeting, a shareholder whose shares are held in the name of a nominee must, in addition to providing notification of participation, register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on 19 November 2024. Such registration may be temporary (so-called voting right registration) and is requested from the nominee in accordance with the nominee's procedures and in such time in advance as the nominee determines. Voting right registrations completed by the nominee not later than 21 November 2024 are taken into account when preparing the share register.

Number of shares and votes

As of the date of this notice there are a total 54,033,447 ordinary shares outstanding in the company that entitle to one vote per share at the general meeting. Furthermore, as of the date of this notice, the company holds 5,908,018 own ordinary shares which cannot be represented at the general meeting. Thus, there are a total of 59,941,465 ordinary shares and votes in the company, of which 54,033,447 shares and votes can be represented at the general meeting.

Proposed agenda

1. Opening of the meeting
2. Election of a chairman of the meeting
3. Preparation and approval of the voting register
4. Approval of the agenda
5. Election of one or two persons to approve the minutes
6. Determination of whether the meeting was duly convened

7. Election and removal of auditor
8. Resolution on change of company category
9. Resolution on amendments to the articles of association
10. Election of board member
11. Closing of the meeting

Election of chairman of the meeting (item 2)

The board of directors proposes that Linnéa Sellström is elected as chairman of the general meeting.

Election and removal of auditor (item 7)

Proposal in accordance with this item will be presented at the latest in connection with the general meeting.

Resolution on change of company category (item 8)

The board of directors proposes that the extraordinary general meeting resolves to change the company's category from public to private.

Resolution on amendments to the articles of association (item 9)

Main proposal - item 9(a)

The resolution to amend the articles of association under this item 9(a) is conditional upon the extraordinary general meeting voting in favour of approving the board of directors' proposal for a resolution on change of company category under item 8 above.

The board of directors proposes that the current 10 § be removed and that the subsequent paragraphs be renumbered, whereby the previous § 11 becomes § 10 and so on. The board of directors also proposes that the extraordinary general meeting resolves on the amendments to the articles of association set out below.

The CEO shall be authorized to make the minor adjustments to this resolution that may be necessary in connection with their registration.

Current wording 1 §

The business name of the company is Calliditas Therapeutics AB. The company is a public company (publ).

Proposed wording 1 §

The business name of the company is Calliditas Therapeutics AB.

Current wording 6 §

The board of directors elected by the shareholders' meeting shall comprise not less than three (3) and not more than ten (10) members.

Proposed wording 6 §

The board of directors shall comprise 1–10 members and not more than 10 alternate members. Where the board of directors comprises 1–2 members, at least 1 alternate member must be appointed.

Current wording 8 §

Notice of shareholders' meetings shall be published in the Swedish Official Gazette and on the company's website, within such time as set forth in the Swedish Companies Act (2005:551). It shall be announced in Svenska Dagbladet that a notice has been issued.

Proposed wording 8 §

Notice of shareholders' meetings shall be given by letter by post, by e-mail or by announcement in the Swedish Official Gazette (Sw. *Post- och Inrikes Tidningar*).

Notice of a shareholders' meetings shall be given no earlier than six and no later than two weeks before the meeting.

Current wording 12 §

The following matters shall be addressed at annual shareholders' meetings:

(...)

(4) Election of one or two persons to attest the minutes;

(...)

Proposed wording 12 §

The following matters shall be addressed at annual shareholders' meetings:

(...)

(4) Where applicable, election of one or two persons to attest the minutes;

(...)

Current wording 13 §

The company's financial year shall be the calendar year.

Proposed wording 13 §

The company's financial year shall be 1 April - 31 March.

Alternative proposal - item 9(b)

If the proposal in item 8 above does not receive the required majority, the board of directors proposes that the extraordinary general meeting resolves to remove the current 10 § of the articles of association and that the subsequent paragraphs be renumbered, whereby the previous 11 § becomes 10 § and so on. The board of directors also proposes that the extraordinary general meeting resolves on the amendments to the articles of association set out below.

The CEO shall be authorized to make the minor adjustments to this resolution that may be necessary in connection with their registration.

Current wording 8 §

Notice of shareholders' meetings shall be published in the Swedish Official Gazette and on the company's website, within such time as set forth in the Swedish Companies Act (2005:551). It shall be announced in Svenska Dagbladet that a notice has been issued.

Proposed wording 8 §

Notice of shareholders' meetings shall be announced in the Swedish Official Gazette (Sw. *Post- och Inrikes Tidningar*). It shall be announced in Svenska Dagbladet that a notice has been made.

Current wording 12 §

The following matters shall be addressed at annual shareholders' meetings:

(...)

(4) Election of one or two persons to attest the minutes;

(...)

Proposed wording 12 §

The following matters shall be addressed at annual shareholders' meetings:

(...)

(4) Where applicable, election of one or two persons to attest the minutes;

(...)

Current wording 13 §

The company's financial year shall be the calendar year.

Proposed wording 13 §

The company's financial year shall be 1 April - 31 March.

Election of board member (item 10)

The board of directors has been informed that the board member Mark E. Hensley, who is also the chairperson of the board of directors, has submitted a request to resign as member of the board of directors whereby his position as member of the board of directors is available.

Proposal in accordance with this item will be presented at the latest in connection with the general meeting.

Special majority requirements

A valid resolution under item 8 above requires that the resolution is supported by all shareholders present at the general meeting and where such shareholders together represent not less than nine-tenths of all shares in the company. A valid resolution under item 9 above requires the support of shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting.

Shareholder's right to obtain information

Shareholders are reminded of their right to, at the general meeting, obtain information from the board of directors and CEO in accordance with Chapter 7 Section 32 of the Companies Act. Shareholders who wish to submit questions in advance may do so by sending post to Calliditas Therapeutics AB (publ), att. Fredrik Johansson, Kungsbron 1 D5, SE-111 22 Stockholm, Sweden, or via e-mail to fredrik.johansson@calliditas.com.

Other information

Proxy forms will be available at the company's office and on Kungsbron 1 D5, SE-111 22 Stockholm, Sweden, and on the company's webpage, www.calliditas.se/en/ at least two weeks before the general meeting. Copies of the documents will be sent to the shareholders who so request and who states their postal address.

Processing of personal data

For information on how your personal data is processed, please see the integrity policy that is available at Euroclear's website, <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

Stockholm, October 2024

Calliditas Therapeutics AB (publ)

The board of directors

This is an in-house translation of the Swedish original wording. In case of discrepancies between the English translation and the Swedish original, the Swedish text shall prevail.